Cevipabulin fumarate TTI-237 fumarate|cas:849550-67-0|西域试剂

Cevipabulin fumarate TTI-237 fumarate,99.97%

产品编号：Bellancom-14949C| CAS NO：849550-67-0| 分子式：C₂₂H₂₂ClF₅N₆O₅| 分子量：580.89

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14949C	￥1680.00	杭州北京（现货）
Bellancom-14949C	￥2880.00	杭州北京（现货）
Bellancom-14949C	￥8880.00	杭州北京（现货）
Bellancom-14949C	￥12400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cevipabulin fumarate TTI-237 fumarate

产品介绍

Cevipabulin fumarate (TTI-237 fumarate) 是一种微管活性的、口服有效的抗肿瘤化合物，可抑制 [³H]长春碱与微管蛋白的结合，对人癌细胞的 IC₅₀ 值为 18-40 nM。

生物活性

Cevipabulin fumarate (TTI-237 fumarate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [³H]NSC 49842 to tubulin, with an IC₅₀ of 18-40 nM for cytotoxicity in human tumor cell line.

体外研究

Cevipabulin (0-50 nM, 72 hours) shows good activity (between 18 and 40 nM IC₅₀ values) on cell lines from ovarian, breast, prostate, and cervical tumors.
Flow cytometry experiments reveal that, Cevipabulin (TTI-237) at low concentrations (20-40 nM) produces sub-G₁ nuclei and, at concentrations above 50 nM, it causes a strong G₂-M block.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	Human cancer cell lines (SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP, and Hela cells).
Concentration:	0-50 nM
Incubation Time:	72 hours
Result:	The IC₅₀ values are 24±8 nM, 21±4 nM, 18±6 nM, 22±7 nM and 40 nM in SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP and Hela cells.

体内研究
(In Vivo)

Cevipabulin (TTI-2370)( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles, in mice) is active by i.v. and p.o. administration against human tumor xenografts, showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nu/nu female mice implanted s.c. in the flank with 1×10⁷ LoVo human colon adenocarcinoma cells.
Dosage:	5, 10, 15, and 20 mg/kg
Administration:	I.V. injection every 4 days for 4 cycles.
Result:	The compound showed dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.

Animal Model:	Athymic nu/nu female mice implanted s.c. in the flank with 1×10⁶ U87-MG human glioblastoma cells.
Dosage:	25 mg/kg.
Administration:	P.O. or I.V. on days 0, 7, 14.
Result:	The compound was active by p.o. or i.v. administration against human tumor xenografts.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nu/nu female mice implanted s.c. in the flank with 1×10⁷ LoVo human colon adenocarcinoma cells.
Dosage:	5, 10, 15, and 20 mg/kg
Administration:	I.V. injection every 4 days for 4 cycles.
Result:	The compound showed dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.

Animal Model:	Athymic nu/nu female mice implanted s.c. in the flank with 1×10⁶ U87-MG human glioblastoma cells.
Dosage:	25 mg/kg.
Administration:	P.O. or I.V. on days 0, 7, 14.
Result:	The compound was active by p.o. or i.v. administration against human tumor xenografts.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nu/nu female mice implanted s.c. in the flank with 1×10⁷ LoVo human colon adenocarcinoma cells.
Dosage:	5, 10, 15, and 20 mg/kg
Administration:	I.V. injection every 4 days for 4 cycles.
Result:	The compound showed dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.

Animal Model:	Athymic nu/nu female mice implanted s.c. in the flank with 1×10⁶ U87-MG human glioblastoma cells.
Dosage:	25 mg/kg.
Administration:	P.O. or I.V. on days 0, 7, 14.
Result:	The compound was active by p.o. or i.v. administration against human tumor xenografts.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (86.07 mM; Need ultrasonic)

H₂O : 1.43 mg/mL (2.46 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7215 mL	8.6075 mL	17.2150 mL
5 mM	0.3443 mL	1.7215 mL	3.4430 mL
10 mM	0.1721 mL	0.8607 mL	1.7215 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献